Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1989733 | 0.90 | SIRT2 (0.40) | GRM5 | |
| SCHEMBL1989636 | 0.90 | SMN1; SMN2 (0.42) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1550616 | 0.88 | FFAR2 (0.37) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1988375 | 0.86 | FFAR2 (0.39) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1988820 | 0.86 | RAB9A (0.45) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL1989363 | 0.86 | KMT2A (0.40) | RAB9AKMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1990276 | 0.86 | GRM5 (0.50) | KMT2AGRM5 | |
| SCHEMBL1993587 | 0.85 | FFAR2 (0.41) | KMT2AALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL1990100 | 0.85 | F2 (0.36) | NPC1RAB9AALDH1A1SMN1; SMN2F2 | |
| SCHEMBL1993913 | 0.85 | ALDH1A1 (0.37) | NPC1RAB9AKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | claimed |
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152236-A1 | AZETIDINE POLYSUBSTITUTED COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | C1R, TACR1, C1S | NPC1 153/4885RAB9A 468/4885KMT2A 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.